Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparison of Different Glomerular Filtration Rate Formulas in the Prediction of Coronary Artery Disease Severity and Extent.

Arquivos brasileiros de cardiologia·2026

Same author

Dealing With Calcium in STEMI: A Unique Case of Intracoronary Fracture and Rescue of a Guide Catheter Extension.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Same author

[Clear Pathway: the role of bempedoic acid in lipid-lowering strategies. The opinion of cardiologists from Piedmont and Aosta Valley, Italy].

Giornale italiano di cardiologia (2006)·2026

Same author

Tc-99m Tetrofosmin SPECT-CT as a Guide to Core Needle Biopsy of a Giant Thymoma.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India·2025

Same author

Obesity and heart failure: Overcoming the paradox.

International journal of cardiology·2025

Same author

Intravascular lithotripsy in calcified left main coronary artery: Time to dare?

International journal of cardiology·2025

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Ivabradine: cardiovascular effects.

Andrea Rognoni¹, Marzia Bertolazzi, Sergio Macciò

¹Catheterization Laboratory, Division of Cardiology, Saint Andrea Hospital, 13100 Vercelli, Italy. arognoni@hotmail.com

Recent Patents on Cardiovascular Drug Discovery

|January 20, 2009

Summary

Ivabradine selectively inhibits the If current in the sino-atrial node, lowering heart rate without affecting cardiac contractility. This mechanism improves cardiac function and stroke volume, offering benefits in various cardiovascular conditions.

Related Experiment Videos

Last Updated: Jun 26, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Area of Science:

Cardiology
Pharmacology

Background:

Ivabradine is a selective If current inhibitor targeting the sino-atrial node.
It offers a unique mechanism for heart rate reduction without impacting cardiac contractility or vascular tone.

Purpose of the Study:

To review the cardiovascular effects of ivabradine.
To summarize recent patents and clinical trial outcomes related to ivabradine.

Main Methods:

Review of experimental and clinical studies on ivabradine.
Analysis of patent literature and clinical trial data.

Main Results:

Ivabradine induces dose-dependent heart rate reduction without adverse effects on atrio-ventricular conduction or ventricular function.
Studies demonstrate efficacy in chronic stable angina, post-myocardial infarction remodeling, and coronary blood flow.
Ivabradine shows a favorable safety profile compared to beta-blockers.

Conclusions:

Ivabradine is an effective and safe agent for heart rate management in cardiovascular diseases.
Its unique pharmacological profile offers therapeutic advantages, particularly in conditions requiring heart rate control.